ABI 220
Alternative Names: ABI-220Latest Information Update: 31 May 2023
At a glance
- Originator Avirmax Biopharma
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Dry age-related macular degeneration
Most Recent Events
- 14 Feb 2023 Early research in Dry age-related macular degeneration in USA (Intravitreous) (Avirmax Biopharma pipeline, February 2023)